Your browser doesn't support javascript.
loading
Considerations for unblinding individual study participants during vaccine trials.
Halsey, Neal; Evans, Stephen; Santosham, Mathuram; Hacker, Adam; Edwards, Kathryn M; Chandler, Rebecca E; Dudley, Matthew Z; Dekker, Cornelia L; Al-Abri, Seif; Arora, Narendra; Buttery, Jim; Dodoo, Alex; Eskola, Juhani; Heininger, Ulrich; Jee, Youngmee; Khuri, Najwa; Obaro, Stephen; Orenstein, Walt; Pitisuttithum, Punnee; Safadi, Marco; Whitney, Cynthia G; Black, Steve.
Afiliação
  • Halsey N; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States. Electronic address: nhalsey1@jhu.edu.
  • Evans S; London School of Hygiene and Tropical Medicine, United Kingdom.
  • Santosham M; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States.
  • Hacker A; Coalition for Epidemic Preparedness Innovations, Norway.
  • Edwards KM; Vanderbilt University, United States.
  • Chandler RE; Coalition for Epidemic Preparedness Innovations, Norway.
  • Dudley MZ; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States.
  • Dekker CL; Stanford University School of Medicine, United States.
  • Al-Abri S; Directorate General for Disease Surveillance and Control, Muscat, Oman.
  • Arora N; Executive Director of The INCLEN Trust International, India.
  • Buttery J; University of Melbourne, Australia.
  • Dodoo A; University of Ghana, Ghana.
  • Eskola J; National Institute for Health and Wellfare, Helsinki, Finland.
  • Heininger U; University of Basel Children's Hospital, Switzerland.
  • Jee Y; Institut Pasteur Korea, Republic of Korea.
  • Khuri N; University of Jordan, Jordan.
  • Obaro S; University of Nebraska Medical Center, United States.
  • Orenstein W; Emory University, United States.
  • Pitisuttithum P; Mahidol University, Thailand.
  • Safadi M; São Paulo School of Medical Sciences, Brazil.
  • Whitney CG; Emory University, United States.
  • Black S; Global Vaccine Data Network, Auckland, New Zealand.
Vaccine ; 41(22): 3399-3402, 2023 05 22.
Article em En | MEDLINE | ID: mdl-37121805
ABSTRACT
Premature unblinding of individual participants is rarely reported in publications, but such unblinding can disrupt vaccine trials by causing worry and drop-out of other participants or "pseudo unblinding," in which participants or investigators over-interpret certain symptoms as being related to receiving an investigational product. This review summarizes appropriate reasons for unblinding in vaccine trials. Regulatory guidance could be improved by distinguishing guidance for vaccine trials from drug trials, with the recognition that unblinding individual participants in vaccine studies is rarely needed for management of adverse events following immunization.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Vacinação Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Vacinação Idioma: En Ano de publicação: 2023 Tipo de documento: Article